relcovaptan

a nonpeptide vasopressin V1 receptor antagonist; structure given in first source

Also Known As:

1-(5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl)pyrrolidine-2-carboxamide; 2-Pyrrolidinecarboxamide, 1-((5-chloro-3-(2-chlorophenyl)-1-((3,4-dimethoxyphenyl)sulfonyl)-2,3-dihydro-3-hydroxy-1H-indol-2-yl)carbonyl)-, (2R-(2alpha(S*),3beta))-; SR 49059; SR-49059

Networked: 21 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - relcovaptan: 21
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - relcovaptan: 21

Experts

1.	Akerlund, Mats: 3 articles (02/2005 - 01/2002)
2.	Bossmar, Thomas: 2 articles (02/2005 - 01/2004)
3.	Steinwall, Margareta: 2 articles (02/2005 - 01/2004)
4.	Lankhuizen, I M: 2 articles (07/2001 - 07/2000)
5.	Saxena, P R: 2 articles (07/2001 - 07/2000)
6.	Schoemaker, R G: 2 articles (07/2001 - 07/2000)
7.	van Veghel, R: 2 articles (07/2001 - 07/2000)
8.	Cenksoy, Cahit: 1 article (03/2014)
9.	Cenksoy, Pinar Ozcan: 1 article (03/2014)
10.	Erdem, Ozlem: 1 article (03/2014)

Related Diseases

1.	Dysmenorrhea (Menstrual Pain) 01/01/2014 - "A selective V(1a)-receptor antagonist, relcovaptan, has shown initial positive results in the treatment of Raynaud's disease, dysmenorrhea, and tocolysis. " 01/01/2002 - "Atosiban and the non-peptide compound, SR 49059, which binds to the two receptors in a similar way as atosiban, are therapeutically effective in dysmenorrhea." 01/01/1998 - "Evidence for an involvement of vasopressin in mechanism of primary dysmenorrhea and effect of the non-peptide vasopressin V1a receptor antagonist, SR 49059, on the uterus of non-pregnant women."
2.	Raynaud Disease (Raynaud's Disease) 05/10/2008 - "Relcovaptan is a selective V1a-receptor antagonist, which has shown initial positive results in the treatment of Raynaud's disease, dysmenorrhoea, and tocolysis. " 01/01/2014 - "A selective V(1a)-receptor antagonist, relcovaptan, has shown initial positive results in the treatment of Raynaud's disease, dysmenorrhea, and tocolysis. "
3.	Infarction (Infarctions) 12/01/2002 - "Treatment with SR-49059 (2 mg/kg), initiated immediately after MCA occlusion, significantly reduced infarction volume (P<0.05) measured at 48 hours after the arterial occlusion. " 12/01/2002 - "Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model." 07/01/2000 - "The vascular responses to [Arg8]-vasopressin were studied in vitro in isolated hearts and mesenteric artery segments of rats with 1-day and 3-week-old infarcts, in absence and presence of the V1a-receptor antagonist SR-49059 and the V2-receptor antagonist OPC-31260. " 08/02/2002 - "This study was designed to compare in vivo hemodynamic effects of early treatment (1-21 days after infarction) with a V(1A) (SR-49059 or ((2S)1-[(2R3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzene-sulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl]-pyrrolidine-2-carboxamide); 0.3 mg/kg/day) and a V(2) (SR-121463B or (1-[4-(N-tert-Butylcarbamoyl)-2-methoxybenzene sulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethyoxy)-cyclo-hexane]indol-2one,furmate; 0.5 mg/kg/day) receptor antagonist in myocardial infarcted rats, chronically instrumented for hemodynamic measurements. "
4.	Myocardial Infarction 01/01/1995 - "Histological examination of the brain, kidneys and heart revealed that the development of fibrinoid necrosis and arterial thickening was not prevented by SR 49059, nor was that of malignant nephroangiosclerosis and of myocardial infarction and fibrosis. " 07/06/2001 - "In the present study, the vasoconstrictor and antidiuretic effects of vasopressin were examined in vivo in conscious rats with chronic myocardial infarction, in the absence or presence of the V(1a) receptor antagonist SR-49059 or the V(2) receptor antagonist OPC-31260. "
5.	Adenoma (Adenomas) 04/01/2006 - "The design of the study included immunohistochemical, pharmacological, and molecular studies on aldosterone-producing adenoma (APA), followed by a monocentric, crossover trial of the orally active V(1a) receptor antagonist, SR 49059, in a double blind, randomized, and placebo-controlled fashion. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	atosiban
3.	Vasopressins (Vasopressin)
4.	mozavaptan
5.	pyrrolidine
6.	indole
7.	Antidiuretic Agents
8.	Vasoconstrictor Agents
9.	Hexanes
10.	Aldosterone

Related Therapies and Procedures

1.	Tocolysis
2.	Injections
3.	Oral Administration